Immedica acquires global rights to pegzilarginase from Aeglea
Stockholm, July 27, 2023 – Immedica announces that it has signed an agreement to acquire the global rights to pegzilarginase and related assets from Aeglea BioTherapeutics, Inc. The acquisition means that the previously entered exclusive license and supply agreement from 2021 of the rights to pegzilarginase in Europe and the Middle East will be superseded. Anders Edvell, Immedica CEO commented: “We are very pleased with this new agreement with Aeglea, giving us the global rights to pegzilarginase. People with arginase 1 deficiency lack sufficient treatment options today and we believe